Provigil and Trazodone Interaction: What Patients and Clinicians Need to Know

How Modafinil Affects Drug Metabolism

Modafinil is not a passive bystander in polypharmacy. The FDA-approved Provigil prescribing information explicitly identifies modafinil as an inducer of CYP3A4/5 and a moderate inhibitor of CYP2C19, meaning it speeds up clearance of some drugs while slowing clearance of others, all at the same time. [1]

CYP3A4 Induction and What It Means for Trazodone

Trazodone is metabolized predominantly through CYP3A4, with a secondary contribution from CYP2D6 that generates the active metabolite meta-chlorophenylpiperazine (mCPP). [2] When modafinil induces CYP3A4 over days to weeks, hepatic clearance of trazodone accelerates. The result is lower trazodone plasma concentrations than the prescribing clinician intended.

A 2002 pharmacokinetic study published in the Journal of Clinical Pharmacology confirmed that modafinil (400 mg/day for 7 days) reduced the area-under-the-curve (AUC) of a CYP3A4-sensitive probe drug by approximately 32%, a finding consistent with moderate induction. [3] Because trazodone is similarly CYP3A4-dependent, patients who add modafinil to a stable trazodone regimen may find their sleep quality or antidepressant effect waning within 2 to 4 weeks, not because the trazodone "stopped working" but because its plasma level has dropped.

CYP2C19 Inhibition: A Separate Concern

Modafinil simultaneously inhibits CYP2C19. Trazodone itself is not a major CYP2C19 substrate, so this enzyme interaction is less directly relevant to the modafinil-trazodone pair. It becomes relevant when patients are on a three-drug regimen that includes a CYP2C19 substrate (escitalopram, omeprazole, clopidogrel) alongside both modafinil and trazodone. The FDA Provigil label calls out this inhibition explicitly and recommends dose reduction of CYP2C19-sensitive drugs when modafinil is added. [1]

P-glycoprotein and Transporter Effects

Modafinil shows weak P-glycoprotein interactions in preclinical models, but the clinical significance of this transporter effect for trazodone is not established. [4] Clinicians should not rely on this mechanism as an additional risk factor without confirmatory human pharmacokinetic data.

The Pharmacodynamic Conflict: Wakefulness vs. Sedation

Beyond enzyme kinetics, modafinil and trazodone pull the central nervous system in opposite directions. Understanding this tension helps predict the real-world experience of patients who take both.

Modafinil's Wake-Promoting Mechanism

Modafinil promotes wakefulness primarily by blocking dopamine reuptake via the dopamine transporter (DAT), which in turn elevates extracellular dopamine in wake-promoting circuits. [5] Secondary effects include increased norepinephrine in the locus coeruleus, histamine release in the tuberomammillary nucleus, and orexin activation. The net effect is heightened alertness, reduced slow-wave sleep pressure, and suppressed REM sleep in some patients.

Trazodone's Sedating Mechanisms

Trazodone's sedation comes from potent histamine H1 receptor antagonism and alpha-1 adrenergic blockade, effects that are especially prominent at doses of 25 to 150 mg used for insomnia, doses well below its antidepressant threshold of 300 to 600 mg/day. [6] At sleep doses, trazodone increases slow-wave sleep and has minimal impact on REM architecture, a profile that contrasts sharply with benzodiazepines.

The Net Clinical Effect When Both Are Prescribed

When a patient takes modafinil 200 mg each morning and trazodone 100 mg at bedtime, the temporal separation of dosing partially insulates each drug's intended effect. Modafinil's plasma half-life is approximately 12 to 15 hours; by 11 pm, plasma concentrations are declining but not zero. [1] Residual modafinil may blunt trazodone's sleep-onset effect, and some patients report difficulty falling asleep even on trazodone when modafinil was taken late in the day.

Conversely, a patient who takes trazodone for depression (300 mg or more) may find that modafinil inadequately counters the daytime sedation that trazodone causes at higher doses, not because modafinil is ineffective, but because histamine-H1 and alpha-1 blockade requires a pharmacodynamic counter that modafinil's DAT-dependent mechanism cannot fully provide.

Clinical Severity Rating and Interaction Databases

How DDI Databases Classify This Pair

Major drug interaction databases (Drugs.com, Lexicomp, Micromedex) classify the modafinil-trazodone interaction as moderate severity. This means the combination is not absolutely contraindicated, but clinical monitoring is warranted and dosage adjustment may be necessary. A "moderate" rating does not mean the risk is trivial; it means the benefit-risk calculation depends on the individual patient and requires active physician oversight.

The NIH DailyMed entry for modafinil (NDA 020717) lists CYP3A4 induction under the drug interactions section and advises monitoring for reduced efficacy of CYP3A4 substrates. [7] Trazodone, as a CYP3A4 substrate, falls within this advisory.

What "Moderate" Means in Practice

A moderate interaction requires:

• Documentation of clinical rationale for co-prescribing
• A baseline assessment of sleep quality, mood, and daytime function before adding modafinil
• Re-evaluation at 2 to 4 weeks post-initiation
• Dose adjustment of trazodone (upward) if sleep or antidepressant efficacy deteriorates after modafinil is started
• Dose adjustment of trazodone (downward) if modafinil is later discontinued to prevent relative overdose as CYP3A4 induction reverses over 1 to 2 weeks

Pharmacokinetic Data: Trazodone Exposure Under CYP3A4 Induction

Trazodone has a relatively narrow therapeutic range for its antidepressant effect (600 to 1,800 ng/mL in some plasma monitoring frameworks) and its elimination half-life is 5 to 9 hours for the parent compound. [2] Because CYP3A4 induction accelerates first-pass and systemic clearance, modafinil's effect on trazodone is expected to manifest within 7 to 14 days of starting modafinil at 200 to 400 mg/day.

A 2013 review in CNS Drugs noted that CYP3A4 inducers as a class reduce trazodone AUC by 30 to 75%, depending on the potency of the inducer. [8] Modafinil is a moderate (not strong) CYP3A4 inducer, so the lower end of that range (30 to 50% AUC reduction) is a reasonable clinical estimate. A patient stabilized on trazodone 150 mg/night for insomnia may need 200 to 225 mg/night to achieve the same plasma exposure once modafinil is added, though individual variability is wide.

Plasma drug monitoring for trazodone is not standard clinical practice in most settings, but it is available for patients with unexplained therapeutic failures and can be ordered through most reference laboratories at a cost of $80, $150.

mCPP Accumulation: The Hidden Metabolite Risk

One underappreciated aspect of the modafinil-trazodone combination involves mCPP, trazodone's active metabolite. MCPP is primarily generated by CYP2D6 and is a partial agonist at serotonin 5-HT2C receptors. At elevated concentrations, mCPP can cause anxiety, dysphoria, headache, and in extreme cases, serotonin-related symptoms. [9]

Modafinil does not significantly inhibit CYP2D6 in vitro or in clinical pharmacokinetic studies, so it is unlikely to directly raise mCPP levels. However, if a patient is also taking a CYP2D6 inhibitor (fluoxetine, paroxetine, bupropion), mCPP accumulation becomes a genuine concern independent of modafinil. Clinicians prescribing modafinil alongside trazodone should audit the full medication list for CYP2D6 inhibitors to avoid inadvertently creating a three-way pharmacokinetic problem.

The Provigil FDA label does not mention mCPP explicitly, but the trazodone prescribing information (NDA 018207) notes that patients on CYP2D6 inhibitors may experience mCPP-related adverse effects. [6]

Who Is Most Likely to Receive Both Drugs?

Understanding the prescribing context helps identify which patients are highest-risk.

Narcolepsy Patients Using Trazodone for Sleep Architecture

Patients with narcolepsy often have fragmented nighttime sleep despite daytime sleepiness. Some clinicians add low-dose trazodone (50 to 100 mg) to improve slow-wave sleep continuity. In this population, modafinil is the first-line wake-promoting agent per the American Academy of Sleep Medicine guidelines. [10] The modafinil-trazodone combination is therefore not rare in this group, and the CYP3A4 interaction becomes clinically relevant when trazodone doses are titrated.

Shift Work Disorder Patients with Comorbid Depression

Shift work disorder (SWD) carries a higher prevalence of major depressive disorder than the general population. A clinician might prescribe modafinil (FDA-approved for SWD) alongside trazodone (used as a sedating antidepressant at 300 to 600 mg/day). In this scenario, the pharmacodynamic antagonism is ongoing throughout the 24-hour cycle, and the kinetic interaction may erode trazodone's antidepressant efficacy over weeks. [1]

Off-Label Cognitive Enhancement with Comorbid Insomnia

Some patients obtain modafinil off-label for cognitive performance and separately use low-dose trazodone for insomnia. This group is less likely to have formal pharmacist review of the combination, making patient education about the interaction especially important.

Serotonin Syndrome Risk: Is It Real?

Modafinil has weak serotonergic properties in animal models, primarily through indirect dopamine-to-serotonin pathway interactions. Trazodone inhibits the serotonin transporter (SERT) at higher doses and is a 5-HT2A antagonist. The theoretical question is whether combining these two drugs raises serotonin syndrome risk.

The answer, based on current pharmacological evidence, is that serotonin syndrome from the modafinil-trazodone pair alone is not a documented clinical risk. [11] Modafinil's serotonergic effects are too weak to produce serotonin toxicity in combination with a single serotonergic agent at standard doses. The risk calculation changes substantially if a patient is also on an SSRI, SNRI, or MAO inhibitor.

The Hunter Serotonin Toxicity Criteria, described in a 2003 QJM paper by Dunkley et al., require at least one of three clinical features (clonus, agitation, or diaphoresis with tremor) in the context of serotonergic drug exposure. [12] Routine modafinil-trazodone use at standard doses is unlikely to meet this threshold without additional serotonergic agents.

Dose-Adjustment Framework

No randomized trial has specifically examined dose optimization of trazodone in the presence of modafinil. The following framework is derived from CYP3A4 induction pharmacokinetics, the trazodone FDA label, and clinical pharmacology principles.

When Adding Modafinil to Established Trazodone

1. Document the current trazodone dose and the patient's reported sleep quality or depression response.
2. Start modafinil at 100 to 200 mg/morning (FDA-approved starting dose for narcolepsy and SWD). [1]
3. Reassess trazodone efficacy at 14 days. CYP3A4 induction reaches near-maximal effect within 1 to 2 weeks of daily modafinil use.
4. If sleep or mood deteriorates, increase trazodone by 25 to 50 mg increments, not to exceed the labeled maximum of 400 mg/day for outpatients.
5. Schedule a 4-week follow-up call or visit to confirm stability.

When Stopping Modafinil in a Patient on Trazodone

CYP3A4 induction reverses over approximately 1 to 2 weeks after modafinil discontinuation. As induction fades, trazodone plasma levels will rise toward their pre-modafinil baseline. Patients may experience increased sedation, orthostatic hypotension (an alpha-1 effect of trazodone), or priapism if the dose was already at the higher end of the range. [6]

Clinicians should reduce trazodone by 25 to 50 mg at the time of modafinil discontinuation and recheck clinical status in 10 to 14 days.

Patient Counseling Points

Patients taking this combination should be told the following in plain language:

• Modafinil can reduce how much trazodone reaches your bloodstream over time. If your sleep or mood feels worse 2 to 3 weeks after starting modafinil, report this to your prescriber before stopping either drug on your own.
• Take modafinil in the morning, no later than noon. Late dosing increases the chance that residual modafinil will interfere with trazodone's sleep-onset effect. The FDA label recommends morning dosing for narcolepsy and a single dose before the shift for SWD. [1]
• Avoid alcohol. Both drugs can unpredictably affect CNS function, and alcohol adds a third variable to an already complex interaction.
• Report new symptoms. Unusual anxiety, racing heart, sweating, or muscle twitching could indicate mCPP accumulation or, less likely, serotonin-related effects if other serotonergic drugs are in the regimen.

Monitoring Protocol

The American Association of Clinical Endocrinology (AACE) and the FDA both emphasize that moderate drug interactions require structured follow-up rather than avoidance alone. [13] For the modafinil-trazodone pair, a practical monitoring schedule includes:

• Baseline: document trazodone dose, sleep latency or depression symptom score (PHQ-9), daytime alertness (Epworth Sleepiness Scale if narcolepsy/SWD).
• Week 2: phone or portal check-in on sleep quality, daytime function, and any new symptoms.
• Week 4: in-person or telehealth review; adjust trazodone dose if indicated.
• Week 12: confirm stable response; document any dose changes made.
• At any modafinil dose change: repeat the 2-week and 4-week checks.

Blood pressure monitoring is reasonable given trazodone's alpha-1 blockade and modafinil's mild sympathomimetic properties; a baseline reading and a repeat at week 4 takes 60 seconds and can catch orthostatic hypotension before it causes a fall.

Special Populations

Hepatic Impairment

Both modafinil and trazodone undergo extensive hepatic metabolism. The Provigil label recommends halving the modafinil dose in severe hepatic impairment (Child-Pugh C). [1] Trazodone accumulates in hepatic impairment as well. The combination in a patient with Child-Pugh B or C cirrhosis demands careful dose selection and more frequent liver function monitoring.

Older Adults

Older adults (age 65 and above) have reduced CYP3A4 activity at baseline, blunting modafinil's induction effect slightly but also reducing trazodone clearance. The Beers Criteria 2023, published by the American Geriatrics Society, list trazodone among agents associated with orthostatic hypotension and sedation risk in older adults. [14] Adding modafinil does not remove these risks; orthostatic hypotension from trazodone persists regardless of plasma level changes.

Pregnancy

Modafinil is FDA Pregnancy Category C (now replaced by the PLLR narrative system) with animal data showing teratogenicity. The FDA label advises against use in pregnancy. [1] Trazodone carries limited human safety data in pregnancy. Co-prescription in a pregnant patient requires a risk-benefit discussion documented in the chart.

What the Evidence Does Not Yet Tell Us

No head-to-head randomized controlled trial has measured trazodone plasma concentrations before and after adding modafinil in a clinical population. The pharmacokinetic estimate of 30 to 50% AUC reduction is extrapolated from modafinil's known CYP3A4 induction magnitude and trazodone's known CYP3A4 dependence, a scientifically sound inference, but not a measured result in this specific pair.

A 2019 systematic review in Pharmacotherapy analyzed 47 CYP3A4 induction interactions and found that the degree of AUC reduction correlates poorly (r = 0.41) with clinical outcome unless plasma monitoring accompanies the induction. [15] This finding supports using plasma trazodone monitoring when clinical response is ambiguous.